Osteoporosis, Post-Menopausal
2 competing products in clinical development for Osteoporosis, Post-Menopausal.
Pipeline by Phase
Phase 31
Approved1
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| raloxifene + Placebo | Eli Lilly | Approved | Completed | 85 |
| teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneous | Eli Lilly | Phase 3 | Completed | 77 |